Smartphone app aims to help black smokers with HIV kick the habit

NCT ID NCT05709002

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study tests a mobile app designed specifically for Black adults living with HIV who smoke daily. The app includes culturally tailored content and anxiety-reduction techniques to support quitting. Participants are randomly assigned to use either the tailored app or a standard quit-smoking app, and their progress is tracked with a smartphone-connected breathalyzer to confirm abstinence. The goal is to see if a personalized digital tool can improve quit rates in this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

mobile app (MASP+)

What this could lead to

If effective, this app could provide a scalable, tailored tool to help Black smokers with HIV quit, reducing smoking-related health disparities.

What could go wrong

This is a small early-stage trial (76 participants), so results may not apply broadly. The app's success depends on user engagement and may not outperform standard quit-smoking apps.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CIGARETTE SMOKING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cigarette Smoking HIV infectious disease Smoking Cessation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.

Contacts and locations

Locations

  • Thomas Street at Quentin Mease Health Center

    Houston, Texas, 77004, United States